The gray market for peptides has exceeded $100 million, largely driven by cryptocurrency and the looksmaxxing trend, according to Chainalysis.
Gray Market Growth
A gray market for peptides has surpassed an annual run rate of $100 million, driven largely by cryptocurrency transactions, according to a recent Chainalysis report.
The surge in this market is tied to the increasing popularity of the "looksmaxxing" trend, which focuses on enhancing physical appearance through various methods, including supplements and cosmetic procedures. Cryptocurrency payments, particularly in Bitcoin and stablecoins, have seen a remarkable rise, with transactions to peptide vendors jumping from around $12 million in Q4 2025 to $32 million in Q1 2026—a staggering 159% increase. Chainalysis forecasts that this market will reach approximately $39 million in the second quarter of 2026.
Market Dynamics
Chainalysis notes that what began as a discreet network among biohackers has transformed into a substantial financial entity, largely due to changing political attitudes and the viral looksmaxxing trend. Peptides, which are short amino acid chains used in medical and cosmetic applications, have gained traction, particularly with the demand for weight-loss alternatives like Ozempic and Wegovy.
Unlike previous online black markets, the current gray market has flourished alongside movements promoting alternative health solutions, particularly during the "Make America Healthy Again" campaign. This evolving market is now processing tens of millions of dollars in cryptocurrency each quarter, positioning it to exceed the $100 million annual mark.
Vendor Preferences
Most vendors in this space prefer using Bitcoin and stablecoins due to banking restrictions on transactions involving unapproved pharmaceuticals. Larger suppliers are increasingly opting for stablecoins to shield themselves from cryptocurrency price volatility. Chainalysis highlighted that among vendors with higher deposits, there is a notable shift towards stablecoins, reflecting a strategic move to protect large orders from price fluctuations.
The report has also identified several Chinese chemical manufacturers that have pivoted to peptide sales after previously supplying drug precursors. This transition allows them to sell finished products directly to consumers, bypassing intermediaries and enhancing profit margins while minimizing legal risks.
